CTLA4 and melanoma: Here, we used a preclinical melanoma model and anti-PD-1/CTLA-4 therapy to show that ICT induces translocation of specific gut bacteria into secondary lymphoid organs and tumors, which activates dendritic cells (DC) and primes anti-tumor T cell responses.